Category:
Prophylactic Biological Products
CAS NO:
1374639-75-4
Standard:
In-house Standards,

Ribociclib is a treatment for advanced breast cancer developed by Novartis Pharmaceuticals.
Indication: HR-positive, HER2-negative Andvance ormetastaticbreast Cancers
All the products under the patent are only for R&D use.
Patent from Novartis Pharmaceuticals, expiry date(The U.S):Jun.27,2028.